Biohaven Pharmaceutical Holding (BHVN) stock forecast for 2022
Last update: 08-19-2022, 9:28Sector: Healthcare
The share price of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) now
What analysts predict:: $153.5
52-week high/low: $151.51 / $79.01
50/200 Day Moving Average: $145.66 / $128.58
This figure corresponds to the average price over the previous 50/200 days. For Biohaven Pharmaceutical Holding stocks, the 50-day moving average is the support level today.
For Biohaven Pharmaceutical Holding stocks, the 200-day moving average is the support level today.
Are you interested in Biohaven Pharmaceutical Holding stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Biohaven Pharmaceutical Holding stock price in 2022. How much will one Biohaven Pharmaceutical Holding share be worth in 2022?
Is it worth taking profit / loss on Biohaven Pharmaceutical Holding stock now or waiting? What are analysts' forecasts for Biohaven Pharmaceutical Holding stock?
We forecast Biohaven Pharmaceutical Holding stock performance using neural networks based on historical data on Biohaven Pharmaceutical Holding stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Biohaven Pharmaceutical Holding stock prediction results are shown below and presented as a graph, table and text information.
Biohaven Pharmaceutical Holding stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Biohaven Pharmaceutical Holding analysts is $153.5.
Today 200 Day Moving Average is the support level (128.58 $).
50 Day Moving Average is the support level (145.66 $).
Historical and forecast chart of Biohaven Pharmaceutical Holding stock
The chart below shows the historical price of Biohaven Pharmaceutical Holding stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Biohaven Pharmaceutical Holding stock price can be found in the table below.
Biohaven Pharmaceutical Holding (BHVN) Forecast for 2022
Biohaven Pharmaceutical Holding information and performance
Biohaven Pharmaceutical Holding Company Ltd., a clinical stage biopharmaceutical company, is developing advanced candidate products targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimehepant, a product that has completed phase III trials for the acute treatment and prevention of migraines; Vasegepant, which has completed phase 2/3 trials for acute treatment and prevention of migraine; and Troriluzole, which has completed phase II / III randomization and is continuing with extended trials for ataxia. The company also offers Troril uzole, which is a phase II / III clinical stage for obsessive-compulsive disorder and Alzheimer’s disease; BHV-0223, product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trials for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III clinical trials for multiple systemic atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine assessment of migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Biohaven Pharmaceutical Holding Address
215 CHURCH STREET, NEW HAVEN, CT, US
Market Capitalization: 10 581 945 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -616 985 024 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 1.314
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 12.53
Enterprise Value (EV) /Revenue
EV To EBITDA: -14.88
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 71495000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Biohaven Pharmaceutical Holding price target for 2021 by month
Target values for the price of one Biohaven Pharmaceutical Holding share for Sep 2022.
Pessimistic target level: 136.07
Optimistic target level: 153.20
Target values for the price of one Biohaven Pharmaceutical Holding share for Oct 2022.
Pessimistic target level: 131.52
Optimistic target level: 151.72
Target values for the price of one Biohaven Pharmaceutical Holding share for Nov 2022.
Pessimistic target level: 134.73
Optimistic target level: 149.54
Target values for the price of one Biohaven Pharmaceutical Holding share for Dec 2022.
Pessimistic target level: 124.66
Optimistic target level: 141.83
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.